Fosfomycin intravenous - Zavante Therapeutics

Drug Profile

Fosfomycin intravenous - Zavante Therapeutics

Alternative Names: Fosfomycin disodium; ZTI-01

Latest Information Update: 15 Jul 2016

Price : $50

At a glance

  • Originator Zavante Therapeutics
  • Developer National Institute of Allergy and Infectious Diseases; Zavante Therapeutics
  • Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Intra-abdominal infections; Skin and soft tissue infections; Urinary tract infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Urinary tract infections
  • Phase II Intra-abdominal infections; Skin and soft tissue infections
  • Phase I Pseudomonal infections

Most Recent Events

  • 15 Jul 2016 Phase-II/III clinical trials in Urinary tract infections (In adults, In the elderly) in Latvia, Slovakia, Greece (IV)
  • 14 Apr 2016 Zavante Pharmaceuticals announces intention to submit NDA to US FDA in Second half of 2017
  • 01 Apr 2016 Phase-II/III clinical trials in Urinary tract infections in USA (IV) (NCT02753946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top